Acetazolamide is an off-label-first-line treatment for idiopathic intracranial hypertension (IIH) used at doses four times higher than approved and with high discontinuation rates due to side effects. This research assesses prescribing patterns and tolerability by dosage, papilledema severity, and potassium supplementation.
✦ The floor
Discussion
Signed responses from readers of the wire.
Audiologists treating patients who report ear-related side effects (including hearing changes or tinnitus) should be aware that high-dose acetazolamide use in idiopathic intracranial hypertension is common off-label and may carry a poorly characterised side-effect burden; flag to referring neurologists but no change to audiology practice itself.
Idiopathic intracranial hypertension can present with auditory symptoms (pulsatile tinnitus, hearing loss), and understanding the side-effect profile of its primary pharmacological treatment is relevant to interdisciplinary care.
- 01Real-world cohort study characterising side effects of acetazolamide in idiopathic intracranial hypertension.
- 02Doses studied were approximately four times higher than the approved label dose.
- 03Published in Expert Review of Neurotherapeutics.
- 04Off-label high-dose use is widespread but safety data remain sparse.
- 05Findings may inform risk-benefit discussions in patients with co-occurring auditory symptoms.
Acetazolamide is used off-label at doses four times higher than approved for idiopathic intracranial hypertension.
studysupportedHigh-dose acetazolamide is associated with a distinct real-world side-effect profile in this population.
studypartially supported- PMID
- 42731033
- DOI
- 10.1080/14737175.2026.2733195.
- Journal
- Expert Review of Neurotherapeutics
- Publication type
- research_article
- Evidence level
- 2b
- Population
- Patients with idiopathic intracranial hypertension receiving acetazolamide
- Intervention
- High-dose acetazolamide (off-label, ~4× approved dose)
Primary outcomes
Characterisation of side effects in real-world use